Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

Movement Sonification as an add-on to Immediate Post-event Psychotherapeutic Intervention in the Management of Acute Stress Disorder: a Feasibility and Acceptability Study

NCT07307937 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-01-15
Last updated
2025-12-29

Condition(s) studied

Acute Stress Disorder Symptoms

Investigational drug(s) / intervention(s)

The sonification of movement is an act studied in this research.

The sonification of movement is an act studied in this research.: The sonification of movement is an act studied in this research at visit 1, visit 2 and visit 3

Study summary

Natural disasters, conflicts, persecution, population displacement, often traumatic migration experiences, and terrorist attacks are all factors that currently expose a significant proportion of the world's population to potentially traumatic events (PTEs). When a person is exposed to a PTE, symptoms of acute stress disorder (ASD) may occur in the immediate aftermath of the PTB, i.e., within the month following the event. These symptoms are dominated by dissociation, which includes depersonalization, i.e., the feeling of being disconnected from one's body. Managing these symptoms can prevent the subsequent onset of post-traumatic stress disorder (PTSD), a serious illness and public health concern. The recommended treatment combines an immediate post-event psychotherapeutic intervention (IPPI) and, where appropriate, medication with anxiolytics from the antihistamine class or antipsychotics

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients aged 18 and over * Who have experienced a potentially traumatic event (PTE) other than the death of a loved one * Who have been referred to the medical-psychological emergency unit (CUMP 93) within one month of the PTE * Who are experiencing acute stress disorder (ASD) according to DSM-5 criteria * Have health insurance * Have signed a written informed consent form Exclusion Criteria: * Severe motor impairment rendering the use of sonification technology impractical * Deaf, mute, or hearing-impaired patients * Adults under guardianship or conservatorship, under judicial protection, or deprived of liberty * Suffering from chronic psychotic disorder or bipolar disorder * Central neurological disease defined by a medical report (including brain damage, cortical or subcortical atrophy, dementia, stroke, transient ischemic attack, head trauma, epilepsy, or seizure) * Presenting a proven severe risk of suicide * Substance use disorder (excluding tobacco) * Pregnant or breastfeeding women * Participation in another interventional study on ESA

Primary outcome measure(s)

  • Evaluate the feasibility of movement sonification in association with IPPI in the treatment of ESA. — 6 weeks
    Success rate, defined as an individual adherence rate of at least two sessions completed with movement sonification out of the three sessions planned.

Trial sites (1)

FacilityCityRegionStatus
Hôpital Avicenne Bobigny France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07307937 on ClinicalTrials.gov ↗ ← All trials in France